NASDAQ:FLNA Cassava Sciences Q1 2026 Earnings Report $0.93 -0.03 (-3.53%) As of 10/2/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Cassava Sciences EPS ResultsActual EPS-$0.21Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACassava Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACassava Sciences Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cassava Sciences Earnings HeadlinesFilana CEO buys 306,813 sharesOctober 4 at 4:02 AM | americanbankingnews.comCassava Sciences (NASDAQ:FLNA) Stock: Insider Richard Barry Buys 100,000 SharesOctober 3 at 4:39 AM | americanbankingnews.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 4 at 1:00 AM | American Hartford Gold (Ad)Cassava Sciences (NASDAQ:FLNA) Stock: Insider Richard Barry Acquires 206,813 SharesOctober 3 at 4:39 AM | americanbankingnews.comCassava Sciences (NASDAQ:FLNA) Stock: Insider Richard Barry Buys 93,091 SharesOctober 2 at 4:38 AM | americanbankingnews.comPositive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research ForwardSeptember 22, 2026 | benzinga.comSee More Cassava Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email. Email Address About Cassava SciencesCassava Sciences (NASDAQ:FLNA) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on simufilam, an investigational oral therapy designed to target an altered form of the scaffolding protein filamin A that Cassava has linked to Alzheimer’s disease pathology. Simufilam has been evaluated in clinical studies involving patients with Alzheimer’s disease, but it is an investigational product and is not approved for commercial use. Cassava Sciences has not marketed any approved products and has primarily operated as a research and development company serving the pharmaceutical and biotechnology markets. Founded in 1998 as Pain Therapeutics, the company adopted the name Cassava Sciences in 2018. It is headquartered in Austin, Texas, and was founded by Remi Barbier, who has served as its chief executive officer. Cassava Sciences is generally associated with the Nasdaq ticker SAVA; the ticker FLNA does not appear to correspond to the company.View Cassava Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestMcDonald's Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
